Eva Johnsson

Computations of earning capability from energy conservation measures

Thomas Olofsson, Eva Johnsson, 2003 .

A Personalized health care approach applied to a Phase IIb study of the glucokinase activator AZD1656

Björn Carlsson, Jesper Havsol, Martin Karpefors, 2012, AMIA.

Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment

Eva Johnsson, P. Fioretto, C. Sjöström, 2016, Diabetologia.

Cardiovascular effects of dapagliflozin in patients with type 2 diabetes and different risk categories: a meta-analysis

Christian Sonesson, Eva Johnsson, C. Sonesson, 2016, Cardiovascular Diabetology.

Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.

Gert Mayer, Ola Samuelsson, Eva Johnsson, 2009, The New England journal of medicine.